Hikma Pharmaceuticals PLC (HKMPF)

Compare

26.64

0.00

(0.00%)

At close: January 27 at 3:00:00 PM EST

Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, today announces that it has entered an exclusive commercial partnership with Emergent BioSolutions (Emergent) for the sale of KLOXXADO® naloxone HCl nasal spray 8 mg in the U.S. and Canada. KLOXXADO® was approved by the US Food and Drug Administration (FDA) in April 2021 for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and p

PR Newswire 14 days ago

HKMPF
0.00%
HKMPY
+3.66%
Is Hikma Pharmaceuticals PLC (HIK.L) Among the U.K. Dividend Aristocrats for 2024?

We recently compiled a list of the U.K. Dividend Aristocrats List: 2024 Rankings by Yield. In this article, we are going to take a look at where Hikma Pharmaceuticals PLC (LON:HIK.L) stands against the other U.K. dividend aristocrats. In recent years, investors have turned away from UK equities, opting instead for global stocks, particularly high-growth options […]

Insider Monkey 30 days ago

HKMPY
+3.66%
^FTSE
Hikma Pharmaceuticals PLC's (LON:HIK) Stock Is Going Strong: Have Financials A Role To Play?

Most readers would already be aware that Hikma Pharmaceuticals' (LON:HIK) stock increased significantly by 5.3% over...

Simply Wall St. last month

HKMPF
0.00%
HKMPY
+3.66%
Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 95% Above Its Share Price

Key Insights Using the 2 Stage Free Cash Flow to Equity, Hikma Pharmaceuticals fair value estimate is UK£37.96 Hikma...

Simply Wall St. 2 months ago

HKMPF
0.00%
HKMPY
+3.66%
Stocks to watch this week: Berkshire Hathaway, Super Micro, Novo Nordisk, Vistry and M&S

Earnings preview of key companies reporting this week and what to look out for.

Yahoo Finance UK 2 months ago

NGG

NGGTF

YUMC
With 55% ownership, Hikma Pharmaceuticals PLC (LON:HIK) boasts of strong institutional backing

Key Insights Significantly high institutional ownership implies Hikma Pharmaceuticals' stock price is sensitive to...

Simply Wall St. 4 months ago

HKMPF
0.00%
HKMPY
+3.66%
Hikma Pharmaceuticals (LON:HIK) shareholders have endured a 17% loss from investing in the stock three years ago

As an investor its worth striving to ensure your overall portfolio beats the market average. But if you try your hand...

Simply Wall St. 4 months ago

HKMPF
0.00%
HKMPY
+3.66%
Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention Day

Hikma Pharmaceuticals in the US joined government officials and non-profit leaders today at a naloxone awareness and training event organized and hosted by Rep. Earl L. "Buddy" Carter of Georgia. This important educational event took place at Groves High School in Savannah, Ga. ahead of National Fentanyl Awareness and Prevention Day.

PR Newswire 5 months ago

HKMPF
0.00%
HKMPY
+3.66%
KLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 months

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the shelf-life extension of KLOXXADO® (naloxone HCl) nasal spray 8mg from 24 to 36 months. KLOXXADO® packaging has been updated with 36-month dating, starting with product manufactured in March 2024.

PR Newswire 5 months ago

HKMPF
0.00%
HKMPY
+3.66%
We Think Hikma Pharmaceuticals' (LON:HIK) Robust Earnings Are Conservative

When companies post strong earnings, the stock generally performs well, just like Hikma Pharmaceuticals PLC's ( LON:HIK...

Simply Wall St. 5 months ago

HKMPF
0.00%
HKMPY
+3.66%
Hikma Pharmaceuticals (HKMPF) Upgraded to Buy: Here's What You Should Know

Hikma Pharmaceuticals (HKMPF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 5 months ago

HKMPY
+3.66%
Hikma Pharmaceuticals PLC Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next

Hikma Pharmaceuticals PLC ( LON:HIK ) investors will be delighted, with the company turning in some strong numbers with...

Simply Wall St. 5 months ago

HKMPF
0.00%
HKMPY
+3.66%
Hikma Pharmaceuticals First Half 2024 Earnings: Beats Expectations

Hikma Pharmaceuticals ( LON:HIK ) First Half 2024 Results Key Financial Results Revenue: US$1.57b (up 10.0% from 1H...

Simply Wall St. 5 months ago

HKMPF
0.00%
HKMPY
+3.66%
Hikma Pharmaceuticals shares surge on upbeat guidance

Shares of Hikma Pharmaceuticals (OTC:HKMPY) (LON:HIK) jumped on Thursday after the company raised its full-year guidance, buoyed by robust performance in its Branded and Generics divisions. At 5:18 am (0918 GMT), Hikma Pharmaceuticals was trading 7.3% higher at £1,975. “The H1 beat was driven by stronger than anticipated performance from the Branded and Generics divisions, reflected in upgrades to FY guidance ranges for both, while Injectables guidance has been maintained as the company expects an H2 weighting for this division,” analysts at RBC said in a note.

Investing.com 5 months ago

HKMPY
+3.66%
Does The Market Have A Low Tolerance For Hikma Pharmaceuticals PLC's (LON:HIK) Mixed Fundamentals?

It is hard to get excited after looking at Hikma Pharmaceuticals' (LON:HIK) recent performance, when its stock has...

Simply Wall St. 6 months ago

HKMPF
0.00%
HKMPY
+3.66%
An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 35% Undervalued

Key Insights Using the 2 Stage Free Cash Flow to Equity, Hikma Pharmaceuticals fair value estimate is UK£29.89 Hikma...

Simply Wall St. 7 months ago

HKMPF
0.00%
HKMPY
+3.66%
With 52% institutional ownership, Hikma Pharmaceuticals PLC (LON:HIK) is a favorite amongst the big guns

Key Insights Significantly high institutional ownership implies Hikma Pharmaceuticals' stock price is sensitive to...

Simply Wall St. 9 months ago

HKMPF
0.00%
HKMPY
+3.66%
Optimism around Hikma Pharmaceuticals (LON:HIK) delivering new earnings growth may be shrinking as stock declines 3.3% this past week

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

Simply Wall St. 10 months ago

HKMPY
+3.66%
Merck's Bridion faces generic threat from drugmaker Hikma

Merck has received a letter that Hikma Pharmaceuticals US unit has sought a pre-patent expiry approval from the US FDA to sell a generic version of its Bridion injection, the drugmaker said in filing on Monday. Merck said, on Feb. 5, it received the letter under the Hatch-Waxman Act, through which a company can seek FDA approval to market a copycat before the expiration of patents related to the brand-name drug. Merck said in the filing that it is currently considering its options.

Reuters 10 months ago

HKMPY
+3.66%
Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facility

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today welcomed Dr. Rahul Gupta, Director of the White House Office of National Drug Control Policy (ONDCP), to its Columbus, Ohio manufacturing facility for a visit and important dialogue on the US opioid overdose epidemic and Hikma's and ONDCP's shared goal of expanding the availability and awareness of life-saving naloxone.

PR Newswire 11 months ago

HKMPF
0.00%
HKMPY
+3.66%

Performance Overview

Return	HKMPF	FTSE 100
YTD	+10.45%	+5.08%
1-Year	+13.93%	+11.77%
3-Year	+7.70%	+12.97%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Hikma Pharmaceuticals PLC (HKMPF)

Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg

Is Hikma Pharmaceuticals PLC (HIK.L) Among the U.K. Dividend Aristocrats for 2024?

Hikma Pharmaceuticals PLC's (LON:HIK) Stock Is Going Strong: Have Financials A Role To Play?

Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 95% Above Its Share Price

Stocks to watch this week: Berkshire Hathaway, Super Micro, Novo Nordisk, Vistry and M&S

With 55% ownership, Hikma Pharmaceuticals PLC (LON:HIK) boasts of strong institutional backing

Hikma Pharmaceuticals (LON:HIK) shareholders have endured a 17% loss from investing in the stock three years ago

Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention Day

KLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 months

We Think Hikma Pharmaceuticals' (LON:HIK) Robust Earnings Are Conservative

Hikma Pharmaceuticals (HKMPF) Upgraded to Buy: Here's What You Should Know

Hikma Pharmaceuticals PLC Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next

Hikma Pharmaceuticals First Half 2024 Earnings: Beats Expectations

Hikma Pharmaceuticals shares surge on upbeat guidance

Does The Market Have A Low Tolerance For Hikma Pharmaceuticals PLC's (LON:HIK) Mixed Fundamentals?

An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 35% Undervalued

With 52% institutional ownership, Hikma Pharmaceuticals PLC (LON:HIK) is a favorite amongst the big guns

Optimism around Hikma Pharmaceuticals (LON:HIK) delivering new earnings growth may be shrinking as stock declines 3.3% this past week

Merck's Bridion faces generic threat from drugmaker Hikma

Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facility

Performance Overview